Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: The Psoriasis Symptoms and Signs Diary

Armstrong, 2012, Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011, PLoS ONE, 7, e52935, 10.1371/journal.pone.0052935 Berth-Jones, 2006, A study examining inter- and intrarater reliability of three scales for measuring severity of psoriasis: Psoriasis Area and Severity Index, Physician’s Global Assessment and Lattice System Physician’s Global Assessment, Br. J. Dermatol., 155, 707, 10.1111/j.1365-2133.2006.07389.x Brodell, 2012, Improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray, J. Drugs Dermatol., 11, 1455 Chren, 1996, Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness, J. Invest. Dermatol., 107, 707, 10.1111/1523-1747.ep12365600 de Arruda, 2001, The impact of psoriasis on quality of life, Br. J. Dermatol., 144, 33, 10.1046/j.1365-2133.2001.144s58033.x Finlay, 1994, Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use, Clin. Exp. Dermatol., 19, 210, 10.1111/j.1365-2230.1994.tb01167.x Gelfand, 2004, Determinants of quality of life in patients with psoriasis: a study from the US population, J. Am. Acad. Dermatol., 51, 704, 10.1016/j.jaad.2004.04.014 Globe, 2009, The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups, Health Qual. Life Outcomes, 7, 62, 10.1186/1477-7525-7-62 Heydendael, 2004, The burden of psoriasis is not determined by disease severity only, J. Invest. Dermatol. Symp. Proc., 9, 131, 10.1111/j.1087-0024.2004.09115.x Javitz, 2002, The direct cost of care for psoriasis and psoriatic arthritis in the United States, J. Am. Acad. Dermatol., 46, 850, 10.1067/mjd.2002.119669 Kurd, 2009, The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003–2004, J. Am. Acad. Dermatol., 60, 218, 10.1016/j.jaad.2008.09.022 Lajevardi, 2015, The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial, Int. J. Dermatol., 54, 95, 10.1111/ijd.12585 Lebwohl, 2014, The psoriasis symptom diary: development and content validity of a novel patient-reported outcome instrument, Int. J. Dermatol., 53, 714, 10.1111/j.1365-4632.2012.05798.x Lebwohl, 2014, Patient perspectives in the management of psoriasis: results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey, J. Am. Acad. Dermatol., 70, 871, 10.1016/j.jaad.2013.12.018 Leino, 2014, Perceived impact of psoriasis on leisure-time activities, Eur. J. Dermatol., 24, 224, 10.1684/ejd.2014.2282 Martin, M.L., McCarrier, K., Bushnell, D.M., Gordon, K., Chiou, C.F., Huang, X., Ortmeier, B., Kricorian, G., 2011a. Validation of the Psoriasis Symptom Inventory (PSI), a patient reported outcome measure. In: 20th European Academy of Dermatology and Venereology Congress, Lisbon, Portugal. Martin, M.L., McCarrier, K., Chiou, C.F., Gordon, K., Kimball, A.B., 2011. Development of a new patient reported measure for assessing symptoms of psoriasis. In: 20th European Academy of Dermatology and Venereology Congress, Lisbon, Portugal. Martinez-Garcia, 2014, Quality of life in persons living with psoriasis patients, J. Am. Acad. Dermatol., 71, 302, 10.1016/j.jaad.2014.03.039 Molina-Leyva, 2014, Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting, J. Drugs Dermatol., 13, 971 Mrowietz, 2014, Psoriasis: to treat or to manage?, Exp. Dermatol., 23, 705, 10.1111/exd.12437 Mustonen, 2014, Psoriasis causes significant economic burden to patients, Dermatol. Ther. (Heidelb.), 4, 115, 10.1007/s13555-014-0053-2 Puzenat, 2010, What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature, J. Eur. Acad. Dermatol. Venereol., 24, 10, 10.1111/j.1468-3083.2009.03562.x Rachakonda, 2014, Psoriasis prevalence among adults in the United States, J. Am. Acad. Dermatol., 70, 512, 10.1016/j.jaad.2013.11.013 Rapp, 2001, Social coping strategies associated with quality of life decrements among psoriasis patients, Br. J. Dermatol., 145, 610, 10.1046/j.1365-2133.2001.04444.x Sampogna, 2012, Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life, Acta Derm. Venereol., 92, 299, 10.2340/00015555-1273 Schmitt, 2014, Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials, Br. J. Dermatol., 170, 274, 10.1111/bjd.12663 Stern, 2004, Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction, J. Invest. Dermatol. Symp. Proc., 9, 136, 10.1046/j.1087-0024.2003.09102.x U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH), 2009. Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Van Voorhees, 2009 Weiss, 2002, Quantifying the harmful effect of psoriasis on health-related quality of life, J. Am. Acad. Dermatol., 47, 512, 10.1067/mjd.2002.122755